Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alogliptin
Drug ID BADD_D00079
Description Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Indications and Usage Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Marketing Status approved
ATC Code A10BH04
DrugBank ID DB06203
KEGG ID D06553
MeSH ID C520853
PubChem ID 11450633
TTD Drug ID D0NJ5H
NDC Product Code 64764-250; 45802-087; 66332-7001; 66332-7003; 45802-103; 11532-7001; 71610-300; 64764-125; 64764-625; 11532-7002; 45802-150; 71610-661; 65392-2813; 50090-5574; 66332-7002; 11532-7003
UNII JHC049LO86
Synonyms alogliptin | 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile | nesina | SYR 322 | SYR322 | SYR-322
Chemical Information
Molecular Formula C18H21N5O2
CAS Registry Number 850649-61-5
SMILES CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute hepatic failure09.01.03.001--Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.000399%Not Available
Altered state of consciousness17.02.04.001; 19.07.01.0030.000399%Not Available
Anaemia01.03.02.0010.000997%
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000399%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.0030.000877%Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.000798%
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.001196%Not Available
Arthralgia15.01.02.0010.002712%
Back pain15.03.04.0050.001555%
Bile duct cancer09.04.02.001; 16.07.01.0010.001196%Not Available
Blister23.03.01.001; 12.01.06.0020.000399%Not Available
Cardiac failure02.05.01.0010.000798%
Cataract06.06.01.0010.000399%
Cerebral haemorrhage17.08.01.003; 24.07.04.0010.000399%Not Available
Cerebral infarction17.08.01.004; 24.04.06.0020.000997%Not Available
Cholecystitis09.03.01.0010.000399%
Colitis ischaemic24.04.08.012; 07.08.01.0040.000399%Not Available
Colon cancer16.13.01.001; 07.21.01.0010.001595%Not Available
Condition aggravated08.01.03.0040.002672%Not Available
Constipation07.02.02.0010.001276%
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.000598%Not Available
Diabetic neuropathy17.09.04.002; 14.07.04.003; 05.07.04.0030.000399%Not Available
Drug eruption08.01.06.015; 23.03.05.001; 10.01.01.0050.002273%Not Available
Dyspnoea exertional02.11.05.005; 22.02.01.0050.001555%Not Available
Eczema23.03.04.0060.001077%
Enterocolitis07.08.03.0030.000598%
Erythema23.03.06.0010.001476%Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene